BR112013016694A2 - ácido nucleico isolado, microrganismo carregador recombinante vivo. anticorpo monocolonal, vacina para caninos contra babesiose, método para a preparação de vacina, uso de polipeptídeo ou fragmento imunogêncio do mesmo, e, kit de teste de diagnóstico - Google Patents

ácido nucleico isolado, microrganismo carregador recombinante vivo. anticorpo monocolonal, vacina para caninos contra babesiose, método para a preparação de vacina, uso de polipeptídeo ou fragmento imunogêncio do mesmo, e, kit de teste de diagnóstico

Info

Publication number
BR112013016694A2
BR112013016694A2 BR112013016694A BR112013016694A BR112013016694A2 BR 112013016694 A2 BR112013016694 A2 BR 112013016694A2 BR 112013016694 A BR112013016694 A BR 112013016694A BR 112013016694 A BR112013016694 A BR 112013016694A BR 112013016694 A2 BR112013016694 A2 BR 112013016694A2
Authority
BR
Brazil
Prior art keywords
vaccine
polypeptide
nucleic acid
isolated nucleic
test kit
Prior art date
Application number
BR112013016694A
Other languages
English (en)
Inventor
Rohwer Andreas
Kleuskens Jos
Moubri-Menage Karina
Petrus Maria Schetters Theodorus
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR112013016694A2 publication Critical patent/BR112013016694A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A61K39/018—Babesia antigens, e.g. Theileria antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/44—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from protozoa

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112013016694A 2010-12-29 2011-12-28 ácido nucleico isolado, microrganismo carregador recombinante vivo. anticorpo monocolonal, vacina para caninos contra babesiose, método para a preparação de vacina, uso de polipeptídeo ou fragmento imunogêncio do mesmo, e, kit de teste de diagnóstico BR112013016694A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10197303 2010-12-29
US201161430298P 2011-01-06 2011-01-06
PCT/EP2011/074120 WO2012089748A1 (en) 2010-12-29 2011-12-28 Canine babesiosis vaccine antigen

Publications (1)

Publication Number Publication Date
BR112013016694A2 true BR112013016694A2 (pt) 2018-05-22

Family

ID=44009896

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013016694A BR112013016694A2 (pt) 2010-12-29 2011-12-28 ácido nucleico isolado, microrganismo carregador recombinante vivo. anticorpo monocolonal, vacina para caninos contra babesiose, método para a preparação de vacina, uso de polipeptídeo ou fragmento imunogêncio do mesmo, e, kit de teste de diagnóstico

Country Status (6)

Country Link
US (2) US20130287786A1 (pt)
EP (1) EP2658568A1 (pt)
JP (1) JP5980810B2 (pt)
BR (1) BR112013016694A2 (pt)
RU (1) RU2599544C2 (pt)
WO (1) WO2012089748A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR100931A1 (es) * 2015-06-22 2016-11-09 Inst Nac De La Tecnología Agropecuaria (Inta) Polipéptido quimérico, vacuna contra la babesiosis, métodos de inmunización, métodos de detección y kit
JP7364264B2 (ja) 2022-02-14 2023-10-18 株式会社クリス・コーポレーション 吊り足場
CN114957406B (zh) * 2022-05-26 2024-02-02 吉林大学 一种犬细小病毒的三价抗原和三价病毒样颗粒以及应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
WO1986006487A1 (en) 1985-04-22 1986-11-06 Commonwealth Serum Laboratories Commission Method for determining mimotopes
ES2068989T3 (es) 1989-02-04 1995-05-01 Akzo Nobel Nv Tocoles como adyuvante en vacunas.
FR2714074B1 (fr) 1993-12-20 1996-03-01 Pasteur Institut Promoteurs des gènes GRA1, GRA2, GRA5 et GRA6 de toxoplasma gondii et vecteurs d'expression comprenant lesdits promoteurs.
EP0691131B1 (en) 1994-06-06 1999-10-06 Akzo Nobel N.V. Babesia vaccine
IL120202A (en) 1996-03-07 2001-03-19 Akzo Nobel Nv Container with freeze-dried vaccine components
US7700359B2 (en) * 2000-06-02 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Gene products differentially expressed in cancerous cells
EP1238983A1 (en) * 2001-03-06 2002-09-11 Akzo Nobel N.V. "Babesia canis vaccine"
JP4446647B2 (ja) * 2001-03-06 2010-04-07 インターベツト・インターナシヨナル・ベー・ベー Ｂａｂｅｓｉａｃａｎｉｓワクチン
BR0312273A (pt) 2002-07-10 2005-04-26 Akzo Nobel Nv Composição imunogênica, vacina, método para a preparação da mesma, e, uso de uma composição imunogênica
BR0313994A (pt) 2002-09-20 2005-07-19 Akzo Nobel Nv Parasita vivo atenuado, vacina para combater infecção parasìtica, uso de um parasita vivo atenuado, método para a produção de uma vacina, e, fragmento de dna
CN101864432A (zh) * 2003-05-07 2010-10-20 英特塞尔股份公司 无乳链球菌抗原ⅰ和ⅱ
US7722879B2 (en) * 2003-07-10 2010-05-25 Intervet International B.V. Babesia vaccines
TWI398272B (zh) 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
RU2380115C1 (ru) * 2008-07-03 2010-01-27 Владислав Валерьевич Белименко Способ получения крови для изготовления антигенов из гемоспоридий
US20100248390A1 (en) * 2009-03-02 2010-09-30 Duke University Compositions and methods for identifying ligands of odorant receptors

Also Published As

Publication number Publication date
US9346862B2 (en) 2016-05-24
EP2658568A1 (en) 2013-11-06
RU2013135002A (ru) 2015-02-10
WO2012089748A1 (en) 2012-07-05
US20150079127A1 (en) 2015-03-19
JP5980810B2 (ja) 2016-09-07
US20130287786A1 (en) 2013-10-31
JP2014505470A (ja) 2014-03-06
RU2599544C2 (ru) 2016-10-10

Similar Documents

Publication Publication Date Title
CY1118576T1 (el) Πρωτεϊνες δεσμευομενες με αντιγονο ανθρωπινης il-23
CL2012000520A1 (es) Anticuerpo o fragmento de union a antigeno del mismo capaz de unirse a dll4 humana; conjugado que comprende a dicho anticuerpo; vector aislado y celula huesped; metodo para producir dicho anticuerpo; composicion farmaceutica que lo comprende; y uso medico de dicho anticuerpo.
BR112015012644A2 (pt) método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
BR112012022210A2 (pt) anticorpo isolado ou seu fragmento imunorreativo, molécula de ácido nucleico, composição farmacêutica, e, uso do anticorpo isolado
WO2013163631A3 (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
BRPI1008145A2 (pt) proteína de ligação de antígeno biespecífico, método para preparação de uma proteína de ligação de antígeno biespecífico, célula hospedeira, composição farmacêutica, uso da proteína de ligação de antígeno biespecífico e método para o tratamento de um paciente.
IL213189A (en) A vaccine containing avian influenza antigen, a method for vaccinating animals with the vaccine, antigen-encoded DNA and its uses
GT201200189A (es) Antagonistas de pcsk9
MX359903B (es) Proteínas estructurales de una mutación del parvovirus como vacunas.
TR201818883T4 (tr) Enfeksiyöz laringotrakeit virüsü ve Newcastle hastalığı virüsü antijenlerini kodlayan rekombinant patojenik olmayan marek hastalığı virüsü yapıları.
BRPI0816330A2 (pt) Composição de polipeptídeo, método para produzir composição de polipeptídeo, construção de polipeptídeo, método para produzir uma construção de polipeptídeo, construção de ácido nucleico, medicamento ou composição de vacina, método para produzir um medicamento ou composição de vacina, e uso da composição de polipeptídeo, de uma construção de polipeptídeo, de uma construção de ácido nucléico ou de um medicamento ou de composição de vacina
BRPI0810211A2 (pt) Citolisina dependente de colesterol mutante purficada, composição, vacina, método para vacinar um paciente, anticorpo monoclonal, ácido nucléico, e, célula hospedeira.
BR112015001102A2 (pt) método de detecção de câncer, droga ou kit e método de seleção de droga terapêutica
BR112013013573A2 (pt) método para produzir anticorpos específicos para um antígeno de interesse, célula b isolada ou recombinante, população de anticorpo, e, anticorpo
BR112014031957A2 (pt) bag3 como soro bioquímico e marcador de tecido
WO2007005627A8 (en) Tuberculosis antigen detection assays and vaccines
BR112013016694A2 (pt) ácido nucleico isolado, microrganismo carregador recombinante vivo. anticorpo monocolonal, vacina para caninos contra babesiose, método para a preparação de vacina, uso de polipeptídeo ou fragmento imunogêncio do mesmo, e, kit de teste de diagnóstico
WO2012049225A3 (de) Markersequenzen für systemischer lupus erythematodes und deren verwendung
BR112012018840A2 (pt) proteínas recombinantes para uso em vacina, anticorpos contra as ditas proteínas e métodos de diagnósticos e terapêuticos incluindo as mesmas
BR112012009412A2 (pt) 'anticorpo anti-hepsina isolado, molécula de ácido nucleico, célula hospedeira, método para fabricar um anticorpo, imunoconjugado, formulação farmacêutica, uso do anticorpo e método para fabricar um anticorpo anti-serina protease'
WO2012042062A3 (de) Markersequenzen für multiple sklerose und deren verwendung
AR083241A1 (es) Metodos y kits para el diagnostico de cancer de prostata
BRPI0818715A2 (pt) proteína m de streptococcus, fragmentos imunogênicos, ácidos nucléicos e métodos de uso
BR112012004847A2 (pt) genoma bohv-4 mutante, vírus bohv-4 mutante, vacina, uso de um vírus bohv-4 mutante, célula, método para a produção de um genoma bohv-4 mutante ou um vírus bohv-4 mutante, e, kit de teste de diagnóstico para diferenciar animais infectados.
WO2010108245A3 (pt) Uso de antígenos de leishmania em método diagnóstico, vacina e terapia para leishmaniose

Legal Events

Date Code Title Description
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]